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Abstract. Fungus-induced asthmatic disease is characterized
by persistent airway hyperreactivity and remodeling.
Objective and design: To determine the role of IL-18 in the
allergic airway response to Aspergillus fumigatus conidia in
a murine model of A. fumigatus-induced asthma. 
Methods: A. fumigatus-sensitized mice were depleted of IL-
18 using a polyclonal anti-IL-18 antibody for 3 days after a
conidia challenge.
Results: Airway hyperresponsiveness and eosinophil num-
bers were significantly elevated 3–30 days after conidia
challenge compared to the normal serum-treated group. His-
tological evidence showed retention of A. fumigatus conidia,
airway remodeling, subepithelial fibrosis, and increased col-
lagen deposition in the lungs of IL-18-depleted mice at day
30 after the conidia challenge. Prolonged retention of conidia
in IL-18 depleted A. fumigatus-sensitized mice was associat-
ed with decreased Toll-like receptor-2 (TLR-2) expression
compared with the control group. 
Conclusions: IL-18 modulates the innate immune response
against A. fumigatus conidia and prevents the development of
severe fungus-induced asthmatic disease. 
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Introduction
Asthma is a respiratory disorder characterized by airway
hyperresponsiveness (AHR) to a variety of specific and non-
specific stimuli, airway inflammation associated with upreg-
ulation of Th2 cells and cytokines, eosinophilia, subepithelial
fibrosis, and excessive mucus production [1]. Sensitization
of individuals to fungal antigens has become particularly
prevalent in recent years, in particular, the ubiquitous fungi,
Aspergillus fumigatus (A. fumigatus) [2]. Individuals with
fungal allergy exhibit similar pathological characteristics to
those observed in asthmatics. In contrast to patients with
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allergic bronchopulmonary aspergillosis (ABPA), subjects
with fungal allergy exhibit little or no evidence of fungal
growth in their lungs, despite the persistence of sensitivity to
fungal antigens [3]. It is clear that the soluble mediators such
as cytokines exacerbate fungus retention [3]. While the
immune response to A. fumigatus antigens in allergic asthma
is assumed to be the result of CD4+ Th2 cells, the effective
clearance of conidia requires a Th1 response, associated with
elevated IL-12 and IFN-g cytokine levels [4]. Therefore, the
elucidation of allergic responses to A. fumigatus and of the
anti-fungal defenses during allergic disease are of clinical
interest.
IL-18 was initially described as an IFNg-inducing factor
that upregulates the IL-12Rb subunit on T cells and has gen-
erally been considered a Th1 type cytokine [5, 6]. IL-18 pro-
motes resolution of bacterial infection [7] and induces fungi-
cidal activity against Cryptococcus neoformans through the
production of IFN-g by NK cells [8]. While the innate
response to fungal infection involves the coordinated action
of IL-18 in the Th1 immune response, little is known about
the anti-fungal role of IL-18 in the context of allergic fungal
disease. 
The present study was designed to define the role of 
IL-18 in experimental fungal asthma. The results presented
herein demonstrate a clear role for IL-18 expression at early
time points following conidia challenge and suggest that the
IL-18 synthesis is essential for the effective clearance of
conidia in the context of allergic fungal airway disease.
Accordingly, immunoneutralization of IL-18 for 3 days fol-
lowing conidia challenge in A. fumigatus-sensitized mice
leads to the retention of conidia within the airways and per-
sistent airway hyperreactivity and peribronchial fibrosis that
is prominent at 30 days after the conidia challenge. 
Materials and methods
Sensitization of mice to A. fumigatus 
Specific-pathogen free (SPF), female CBA/J mice (Jackson Laborato-
ries; Bar Harbor, ME) were maintained in a SPF facility for the duration
of this study. Prior approval for mouse usage in the development of the
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allergic fungal asthma model described herein was obtained from Uni-
versity Laboratory Animal Medicine facility at the University of Michi-
gan Medical School. Sensitization of mice to a commercially available
preparation of soluble A. fumigatus antigens (Greer Laboratories,
Lenoir, NC) was performed as previously described in detail [9].
Briefly, mice received a total of 10mg of A. fumigatus antigens dissolved
in 0.2 ml of IFA (Sigma, St. Louis, MO) distributed equally between the
peritoneal cavity and s.c. Two weeks later, and for three subsequent
weeks, mice received a total of 20 mg of A. fumigatus Ag, dissolved in
normal saline, via the intranasal route. One week after the third
intranasal challenge, each mouse received 5.0 ¥ 106 live A. fumigatus
conidia, strain 13073, suspended in 30 ml of 0.1% Tween-80 via the
intratracheal route [10]. 
Production of anti-IL-18 Abs and immunoneutralization 
of IL-18
Rabbit anti-murine IL-18 Ab were prepared by multiple-site immuniza-
tion of New Zealand White rabbits with recombinant murine IL-18
(R&D Systems, Rochester, MN) in CFA. The polyclonal Ab was titered
by direct ELISA and specifically verified by the failure to cross-react to
other murine cytokines or chemokines. As a control, preimmune normal
rabbit serum (NRS) was used. The endotoxin content in IL-18 antiserum
and NRS was below detection level (< 0.05 EU/ml PYROGENT;
BioWhittaker, Walkersville, MD). In depletion studies, mice were pre-
treated with polyclonal rabbit anti-murine IL-18 antibodies (0.5 ml,
titers of 106/ml) given intraperitoneally 1h prior to intratracheal admin-
istration of conidia and 2 days post conidia. The volume of antiserum
was considered to be sufficient to neutralize systemic endogenous IL-
18 in that the biological half-life of the antibody was ~ 48 h (C.M.
Hogaboam, unpublished observation). Control animals received 0.5 ml
of normal rabbit serum (NRS). Airway physiology and function was
assessed 3, 7, and 30 days following conidia challenge. 
Measurement of bronchial hyperresponsiveness
Immediately prior to and at days 3, 7, and 30 after the intratracheal A.
fumigatus conidia challenge, bronchial hyperresponsiveness in A. fumi-
gatus-sensitized mice was assessed in a BuxcoTM plethysmograph (Bux-
co, Troy, NY) [11]. Mice were anesthetized with sodium pentobarbital
(40 mg/ml i.p.; Butler Co., Columbus, OH) prior to their intubation for
ventilation with a Harvard pump ventilator (Harvard Apparatus, Reno,
NV). The following ventilation parameters were used: tidal volume =
0.25 ml, breathing frequency = 120/min, and positive end-expiratory
pressure ~ 3 cm H2O. Within the sealed plethysmograph mouse cham-
ber, transpulmonary pressure (i.e. tracheal pressure – mouse chamber
pressure) and inspiratory volume or flow were continuously monitored
online by an adjacent computer. Airway resistance was calculated online
via computer software (Buxco, Troy, N.Y.), and was determined by the
division of the transpulmonary pressure by the change in inspiratory
volume. Following a baseline period in the Buxco apparatus, anes-
thetized and intubated mice received a dose of 1 mg of methacholine by
tail vein injection, and airway responsiveness to this non-selective bron-
choconstrictor was again calculated online. At the conclusion of the
assessment of airway responsiveness, each mouse was killed by ex-
sanguination, and a bronchoalveolar lavage (BAL) was performed with
1ml of normal saline. Approximately 500 ml of blood was also collect-
ed from each mouse and transferred to a microcentrifuge tube. Sera
were obtained after the sample was centrifuged at 15000 rpm for 
10 min. Whole lungs were finally dissected from each mouse and snap
frozen in liquid N2 or prepared for histological analysis.
Morphometric analysis of leukocyte accumulation 
in BAL samples
Neutrophils, macrophages, eosinophils, and lymphocytes were quanti-
fied in bronchoalveolar lavage fluid (BALF) samples applied to coded
microscope slides using a cytospin (Shandon Scientific, Runcorn, UK).
Identification of each cell type in the cytospins was facilitated by dif-
ferential staining with Wright-Giemsa differential stain and expressed
as a percentage of total cells after counting 300 cells in 10–20 high
power fields (1000¥) per slide. A total of 1 ¥ 106 BAL cells were spun
onto each slide to compensate for differences in cell retrieval. 
ELISA analysis
Murine IL-18, MIP-2, IFN-g, TNF-a, eotaxin, RANTES, and IL-12
protein levels were determined in 50 ml of whole lung homogenates,
using a standardized sandwich ELISA technique previously described
in detail [12]. Whole lungs were homogenized in 1 ml of normal sa-
line containing 1 mg of protease inhibitor (Complete‰, Boehringer
Mannheim, Indianapolis, IN) with a Tissue Tearor. Recombinant murine
IL-18 was used to generate the standard curves from which the concen-
trations present in the samples were derived. The limit of ELISA detec-
tion for IL-18 was consistently above 50 pg/ml and the ELISA was
screened to ensure the specificity of each antibody used. MMP-2 activ-
ity was measured in 100 ml samples of cell culture supernatants using
MMP-2 ELISA activity assay system (Amersham Pharmacia Biotech,
Piscataway, NJ) according to the manufacturer’s directions. 
Whole lung histological analysis
Whole lungs from A. fumigatus-sensitized mice prior to and after A.
fumigatus conidia challenge were fully inflated by intratracheal per-
fusion with 4% paraformaldehyde. Lungs were then dissected and
placed in fresh paraformaldehyde for 24 h. Routine histological tech-
niques were used to paraffin-embed this tissue, and 5-mm sections of
whole lung were stained with hematoxylin and eosin, Masson
trichrome, Periodic Acid Schiff (PAS), and Gomori methanamine silver
(GMS).
Preparation of cDNA and reverse transcriptase (RT)-PCR
amplification
Total RNA samples were prepared from whole lung samples removed
from A. fumigatus sensitized mice at days 0, 3, 7, and 30 after conidia
challenge. RNA from specific samples was reverse transcribed into
cDNA utilizing a BRL reverse transcription kit and oligo (dT) 12–18
primer. The amplification solution contained 50 mM KCl, 10 mM Tris-
HCl (pH 8.3), and 2.5 mM MgCl2. Specific oligonucleotide primers
were added (200 ng/sample) to the buffer, along with 5 ml of reverse
transcribed cDNA sample. The following oligonucleotide primers were
used: TLR2 primer sequences: sense, 5¢CTCAGGATAGGAAATGT-
AGAGACT 3¢; antisense, 5¢AATCGCCGAGCCCATTGAGGGTA 3¢,
426-base-pair (bp) product. b-actin primer sequences: sense, 5¢GC-
TCGGCCGTGGTGGTGAAGC 3¢; antisense, 5¢GTGGGGCGCCCC-
AGGCACCA 3¢, 450-bp product. 
The cDNA was amplified using the following cycling parameters:
the mixture was first incubated for 4 min at 94°C and then cycled 32
times at 94°C for 45 sec, 55°C for 45 sec, and elongated at 72°C for 
45 sec. After amplification the samples were separated on a 2% agarose
gel containing 0.3 mg/ml of ethidium bromide, and bands were visual-
ized and photographed using a translucent UV source.
Statistical analysis
All results are expressed as mean ± standard error of the mean (SEM)
from 2 repeated studies. Analysis of variance (ANOVA) and Dunnett’s
test for multiple comparisons were used to determine statistical signifi-
cance in both groups at various times after conidia challenge; P < 0.05
was considered statistically significant.
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Results
IL-18 levels are elevated in whole lung following conidia
challenge in A. fumigatus-sensitized mice
To determine the temporal expression of IL-18 in A. fumiga-
tus-sensitized mice following conidia challenge, IL-18 levels
in whole lung homogenates were measured by ELISA. IL-18
levels measured in whole lung homogenates from naive mice
were increased following A. fumigatus sensitization prior to
conidia challenge (10.1 ± 1.2 to 18.0 ± 2.4 ng/mg protein).
IL-18 was significantly elevated above these levels at day 3
(P < 0.05; 26.8 ± 4 ng/mg protein) after conidia challenge
(Fig. 1), however, levels returned to baseline after day 3.
Since IL-18 levels were significantly elevated up to day 3
after conidia, anti-IL-18 antiserum or normal rabbit serum
was administered to mice from days 0 to 3 after conidia. Anti-
IL-18 antiserum effectively attenuated IL-18 levels com-
pared with NRS controls (Fig. 1).
IL-18 immunoneutralization does not alter IL-12 or IFN-g
levels in whole lung homogenates from allergic mice
IL-18 has been shown to induce the expression and release of
IFN-g from T cells and macrophages in combination with IL-
12 [8]. Therefore, to determine the effect of IL-18
immunoneutralization on the levels of IFN-g and IL-12, both
cytokines were measured via ELISA in whole lung
homogenates from A. fumigatus-sensitized mice at 0, 3, 7, and
30 days after intratracheal conidia challenge in mice treated
with either NRS or polyclonal anti-IL-18 Abs for the first 3
days after conidia challenge (Figs. 2A and B). Significantly
elevated levels of IFN-g (P < 0.01) and IL-12 (P < 0.05) were
measured in whole lung homogenates 3 days after conidia
challenge in A. fumigatus-sensitized mice, however, by day 7
both cytokines were detected at levels similar to those mea-
sured at day 0. Following immunoneutralization of IL-18 at
day 0–3 following intratracheal conidia administration, no
significant differences in IFN-g (Fig. 2A) or IL-12 (Fig. 2B)
levels were detected between the two groups. This data
demonstrates that IL-18 immunoneutralization does not
affect whole lung levels of IL-12 or IFN-g after conidia chal-
lenge in A. fumigatus-sensitized mice.
IL-18 neutralization alters eosinophil and neutrophil
recruitment in the airways of  A. fumigatus-sensitized mice
Leukocytes accumulating in the lung during allergic asthma
play multiple roles in the pathogenesis of the disease. How-
ever, these cells also exert a major effect on the clearance of
airborne pathogens. For example, whereas eosinophils have
been shown to exacerbate fungal allergic disease [2, 9, 13],
neutrophils recruited to the lung during fungal infection play
a key role in early killing of the fungal conidia [3]. Therefore,
leukocyte recruitment into the lung following conidia chal-
lenge was monitored for up to 30 days in A. fumigatus-sensi-
tized mice treated with NRS or polyclonal anti-IL-18 Abs
between days 0–3. 
The percentage of neutrophils in BALs from A. fumiga-
tus-sensitized mice increased significantly 3 days after coni-
dia challenge (Fig. 3A). Following immunoneutralization of
Fig. 1. IL-18 levels in whole lung homogenates from A. fumigatus-sen-
sitized mice prior to, and at 3, 7, or 30 days post, intra-tracheal conidia
challenge measured by a specific ELISA. Mice were treated with NRS
(solid circles) or polyclonal anti-IL-18 antibodies (filled circles) 1 h
prior to conidia challenge and 2 days post challenge. Results show mean
± SEM from 5 mice at each time point. *P < 0.05 denotes significant
induction of IL-18 production compared to levels measured prior to
conidia challenge, t = 0. 
Fig. 2. IFN-g (A) or IL-12 (B) levels in whole lung homogenates from
A. fumigatus-sensitized mice prior to, and at 3, 7, or 30 days post, intra-
tracheal conidia challenge measured by a specific ELISA. Mice were
treated with NRS (solid circles) or polyclonal anti-IL-18 antibodies
(filled circles) 1h prior to conidia challenge and 2 days post challenge.
Results show mean ± SEM from 5 mice at each time point. *P < 0.05 or
**P < 0.01 denotes significant induction of IFN-g or IL-12 production
compared to levels measured prior to conidia challenge, t = 0. 
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IL-18, significantly (P < 0.05) fewer neutrophils were count-
ed in recovered BAL at day 3 (Fig. 3A), while neutrophils
were absent at day 7 in both groups. In contrast, 30 days after
conidia challenge in anti-IL-18-treated mice, neutrophil
numbers were significantly increased compared to NRS-
treated controls. 
Eosinophil numbers within the BAL were elevated in
NRS and anti-IL-18-treated mice at days 3 and 7 after coni-
dia challenge, though significantly greater numbers were
counted in the BALs from anti-IL-18-treated mice (Fig. 3B).
Thirty days following conidia challenge, eosinophils were
not present in BAL from NRS-treated controls, however,
eosinophil numbers remained significantly elevated
(P < 0.05) in anti-IL-18-treated mice at this time point. Taken
together, this data suggested that immunoneutralization of
IL-18 causes significant alterations in the recruitment of both
neutrophils and eosinophils to the allergic airway. 
IL-18 neutralization does not alter MIP-2, TNF-a, or 
eotaxin release 3 days after conidia challenge
To determine the role of cytokine and chemokine release 3
days after conidia challenge on leukocyte accumulation at
this time point, levels of cytokines and chemokines that are
involved in the recruitment of eosinophils and neutrophils,
such as eotaxin, MIP-2, RANTES, and TNF-a, were mea-
sured. Three days after conidia challenge in A. fumigatus-
sensitized mice, significantly elevated levels of MIP-2 and
TNF-a were observed (Table 1). However, no significant dif-
ference in the whole lung levels of these cytokines were
denoted between NRS and anti-IL-18-treated mice at this
time point (Table 1). In contrast, eotaxin and RANTES lev-
els in whole lung homogenates were not significantly elevat-
ed 3 days after conidia challenge, and anti-IL-18 antiserum
treatment did not further change the levels of these
chemokines measured in the lung (Table 1). This data
demonstrates that IL-18 immunoneutralization does not
affect whole lung levels of MIP-2, TNF-a, or eotaxin after
conidia challenge in A. fumigatus-sensitized mice.
Neutralization of IL-18 exacerbates airway 
hyperresponsiveness
Following intratracheal challenge with live A. fumigatus
conidia, A. fumigatus-sensitized mice exhibit chronic AHR
to intravenously administered methacholine up to 30 days
after conidia challenge, as demonstrated in previous studies
[14–16]. Studies utilizing IL-18 deficient mice or IL-18
immunoneutralization methods have shown exacerbation of
AHR in several acute allergic murine models in the absence
of IL-18 [17, 18]. We have also shown that the eosinophil has
a prominent role in the acute AHR to soluble A. fumigatus
antigen challenge [9]. To assess the role of IL-18
immunoneutralization on AHR in the present study, intra-
venous administration of 1 mg methacholine which caused
no significant increase in AHR above basal levels (2.4 ±
Fig. 3. Neutrophil (A) and eosinophil (B) counts in BAL samples from
A. fumigatus-sensitized mice treated before, and at various times after,
A. fumigatus conidia challenge. Mice were treated 1 h prior to, or 2 days
after, conidia challenge with NRS (solid circles) or anti-IL-18 polyclon-
al antibodies (open circles). BAL cells were dispersed onto microscope
slides using a cytospin; neutrophils and eosinophils were differentially
stained with Wright-Giesma stain. A minimum of 15 high powered
fields or 300 cells were examined in each cytospin. A total of 1 ¥ 106
BAL cells were cytospun onto each slide to compensate for differences
in cell retrieval from each mouse. Values are expressed as mean ± SEM
of the percentage of cells based total cells counted/sample. *P < 0.05 or
**P < 0.01 denotes significant differences in neutrophil or eosinophil




Day 0 0.4 ± 0.01 0.4 ± 0.05
Day 3 2.4 ± 0.9* 2.5 ± 0.2*
TNF-a
Day 0 0.3 ± 0.03 0.5 ± 0.03
Day 3 3.7 ± 0.8* 3.9 ± 0.08*
Eotaxin
Day 0 0 ± 0 0 ± 0
Day 3 0.02 ± 0.01 0.04 ± 0.01
MIP-2, TNF-a, or eotaxin levels in whole lung homogenates from A.
fumigatus-sensitized mice prior to, and at 3 days post, intra-tracheal
conidia challenge measured by a specific ELISA. Mice were treated
with NRS or polyclonal anti-IL-18 antibodies 1h prior to conidia chal-
lenge and 2 days post challenge. Results show mean ± SEM from 5
mice at each time point. *P < 0.05 denotes significant induction of
cytokine or chemokine production compared to levels measured prior to
conidia challenge, t = 0.
Evidence for chronic inflammation and airway remodeling
following IL-18 neutralization 
Administration of live A. fumigatus conidia to mice previ-
ously sensitized to A. fumigatus has been shown to cause
subepithelial/peribronchial fibrosis [16]. Increased collagen
deposition and peribronchial fibrosis, a sign of chronic
inflammation, is readily visualized by Masson Trichrome
staining at various times following conidia challenge [16]
(Fig. 6A). In the present study, the greatest staining was seen
at day 30 after conidia in NRS-treated mice. However, in
anti-IL-18-treated mice, subepithelial fibrosis was markedly
increased above that seen in the NRS control group (Fig.
6B). The histological analysis suggested that IL-18
immunoneutralization lead to chronic and persistent airway
remodeling. 
IL-18 regulates TLR2 expression in A. fumigatus-sensitized
mice during conidia challenge
To further investigate the mechanism for conidia persistence
within the lungs, we measured the levels of receptors
involved in the innate immune response that are thought to
recognize fungal components. TLR-2 is involved in inducing
anti-fungal responses in Drosophila [19], and recent studies
have indicated a role for these receptors in innate responses
mediated by products of various infectious agents [20]. We
examined the expression of TLR2 mRNA in whole lungs
from non-sensitized mice receiving conidia alone or A. fumi-
gatus-sensitized animals following IL-18 immunoneutraliza-
tion to determine whether the expression of this receptor is
modulated by IL-18. TLR2 mRNA was expressed constitu-
tively in the lungs of non-sensitized mice prior to conidia
challenge (64.4 ± 2.0 b-actin/TLR2 ratio; Fig. 7A) and
increased significantly at days 21 (P < 0.05) and 30
(P < 0.001) after the conidia challenge. In contrast, TLR2
mRNA expression was absent in mice previously sensitized
to A. fumigatus prior to the conidia challenge (Fig. 7B) but
was significantly elevated 3, 7 (P < 0.05) and 30 (P < 0.001)
days after conidia challenge in these mice (Fig. 7B). Inter-
estingly, TLR2 mRNA levels induced after conidia challenge
in the sensitized mice were approximately 10 fold lower than
that observed in non-sensitized mice. IL-18 immunoneutral-
ization further decreased the levels of TLR2 mRNA in whole
lung samples after conidia challenge; TLR2 mRNA was not
significantly (P < 0.0001) elevated until 30 days after conidia
challenge in mice that received IL-18 antibodies 0 to 3 days
after conidia challenge (Fig. 7C). Taken together, these data
suggest that A. fumigatus sensitization delays TLR2 mRNA
upregulation and that anti-IL-18 treatment further delays
TLR2 expression. The lack of TLR2 strongly correlates with
the retention of conidia in the airway. 
Discussion
Previous studies demonstrate that IL-12- and IL-18-induced
IFN-g production is essential for the clearance of fungal
infection [8]. However, in the case of allergic fungal disease,
the initial, early Th1 response is followed by a vigorous Th2
response. At present, the role that IL-18 plays in the early
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0.5 cm H2O/ml/s; Fig. 4), was used. Immuno-neutralization
of IL-18 in A. fumigatus-sensitized mice significantly
(P < 0.05) elevated AHR at day 3 and 30 after the conidia
challenge compared to NRS-treated controls (Fig. 4). These
data show that immunoneutralization of IL-18 accelerates
and prolongs the extent of allergic airway hyperresponsive-
ness. 
A. fumigatus persistence within the lungs following IL-18
immunoneutralization 
Neutrophils play a key role in the removal of conidia follow-
ing pulmonary infection. Since BAL neutrophil numbers
were significantly decreased following IL-18 immunoneu-
tralization, we examined whether A. fumigatus persisted in
the lungs of these mice. The presence of fungus within the
lungs was histologically examined using GMS stain, which
appears black in the presence of the polysaccharide compo-
nents from the fungus cell wall. Fig. 5a demonstrates the
presence of few fungal conidia in the airways of NRS-treat-
ed control animals, however, a significant increase in stain-
ing was seen in anti-IL-18-treated mice (Fig. 5B). Although
increased fungal staining was observed in these mice, there
was no evidence of hyphal formation or fungal colonization.
H&E staining of whole lung sections demonstrated granulo-
matous formations associated with the areas of fungal per-
sistence in the lungs of anti-IL-18-treated (Fig. 5C), but not
control mice (data not shown). Thus, the acute 3-day
immunoneutralization of IL-18 results in the persistence of
fungal conidia with the lungs thereby promoting the forma-
tion of granulomatous regions. This feature probably reflects
the fact that neutrophil recruitment was impaired into the air-
ways of anti-IL-18-treated mice.
Fig. 4. Airway hyperresponsiveness in A. fumigatus-sensitized mice
prior to, and at various times after, A. fumigatus conidia challenge.
Changes in airway resistance or hyperresponsiveness (units = cm
H2O/ml/s) were monitored at each time point by the intravenous injec-
tion of methacholine in mice treated with NRS (open bars) or polyclon-
al anti-IL-18 antibodies (filled bars). The dashed line indicates airway
resistance measured in both groups in the absence of methacholine (i.e.
baseline resistance). Values are expressed as mean ± SEM;
n = 5–7/group/time point. *P < 0.05 denotes significant changes in air-
way resistance compared to NRS-treated control groups.
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Th1, or later Th2, response in fungal-induced asthma is
unclear. The present study was designed to investigate the
role of this cytokine during chronic development of allergic
fungal disease. IL-18, IFN-g, and IL-12 levels in whole lung
homogenates were significantly elevated 3 days after conidia
challenge in this model of fungal induced allergic asthma.
Previous studies have shown that IL-18, released from alve-
olar macrophages or airway epithelial cells [21, 22], in con-
cert with IL-12, induces IFN-g secretion from alveolar
macrophages, T cells, and NK cells [8, 21, 23]. Since the
coordinated expression of these Th1-type cytokines plays a
key role in the defense against fungal colonization [8, 24],
these observations suggest that IL-18 may regulate the initial
host response to A. fumigatus conidia. The present study
demonstrated that IL-18 expression subsequent to the intra-
tracheal administration of live A. fumigatus conidia in A.
fumigatus-sensitized mice plays a key role in the clearance of
conidia from the lungs. The lack of fungus clearance from
anti-IL-18-treated mice further compounded AHR,
eosinophilic lung inflammation, and peribronchial fibrosis. 
Fig. 6. Masson trichrome-stained whole lung sections 30 days after conidia challenge showing the extent of collagen deposition (light blue staining)
around small airways and adjacent blood vessels. Sections were taken from A. fumigatus-sensitized mice treated with NRS (A) or anti-IL-18 anti-
bodies (B) between day 0–3 after conidia challenge. Greater amounts of collagen were apparent around the airways from mice treated with anti-IL-
18 antibodies compared with NRS. Original magnification was 200 ¥ for each photomicrograph.
Fig. 5. Representative photomicrographs of GMS-stained whole lung sections from A. fumigatus-sensitized mice 30 days after conidia challenge.
Mice were treated with NRS (A) or anti-IL-18 polyclonal antibodies (B) between day 0–3 after conidia challenge. GMS staining was evident in alve-
olar macrophages in whole lung sections from IL-18 depleted mice as shown by the arrow (B) but was absent in similar sections from NRS-treated
control lungs (A). (C) shows a representative photomicrograph of hematoxylin and eosin-stained whole lung section from A. fumigatus-sensitized
mice 30 days post conidia challenge treated with IL-18 antibodies showing granuloma formation within the lungs. Original magnification was 200 ¥.
In agreement with previous studies, IL-18 immunoneu-
tralization did not alter IL-12 or IFN-g levels in whole lung
homogenates compared to control-treated animals [18, 25].
IL-18 has previously been shown to synergize with IL-12 to
induce the production of IFN-g from NK cells and
macrophages via upregulation of the IL-12Ra subunit [8,
23], however, it is unable to induce the release of IFN-g inde-
pendently. While IL-18 does not alter IL-12 or IFN-g levels
in whole lung homogenates, conidia clearance from the lungs
of A. fumigatus-sensitized mice is clearly delayed following
IL-18 immunoneutralization. This suggests that IL-18 has an
integral role in the initial host immune response to fungal
conidia that is independent of IFN-g or IL-12 expression in
the allergic host. Anti-IL-18 treatment was associated with
significantly decreased neutrophil accumulation in the BAL
at 3 days after conidia challenge in A. fumigatus-sensitized
mice. Since neutrophils have been shown to be intimately
involved in the clearance of conidia from the lungs [26],
decreased neutrophil migration into the airways of anti-IL-
18-treated mice probably allowed the retention of conidia.
The decreased neutrophil tissue accumulation noted in this
research coincides with a previous study by Netea et al [27]
who showed that neutrophil recruitment in a murine model of
Escherichia coli-induced endotoxemia was defective after
anti-IL-18-treatement. They also suggested that this defect
was mediated via several pathways involving decreased 
IFN-g, macrophage inhibitory protein-2 (MIP-2), TNF-a,
and ICAM-1 expression. In the context of allergic airway dis-
ease, no significant differences in whole lung levels of IFN-
g, TNF-a, or MIP-2 were detected at 3 days following coni-
dia challenge in anti-IL-18-treated mice compared with
NRS-treated controls, but changes in the levels of these
cytokines or chemokines may have occurred at earlier time
points. In contrast to the decrease 3 days after conidia chal-
lenge, a significant increase in BALF neutrophil numbers
was noted 30 days after conidia challenge. This observation
may be a result of persistent conidia or subsequent pul-
monary infections such as pneumonitis.
The increased AHR after conidia challenge in anti-IL-18-
treated mice correlated with increased peribronchial and
BALF eosinophilia. Elevated airway hyperresponsiveness
accompanied by BALF eosinophilia and elevated IgE levels
have previously been described following neutralization of
IL-18 or in IL-18 deficient murine models of acute aller-
gic lung disease [17, 18]. Campbell et al [17] showed that 
IL-18 immunoneutralization allergen-associated eosinophil
accumulation could be induced 8 h after cockroach allergen
challenge in mice previously sensitized to cockroach aller-
gen. Furthermore, corroborating the results of the present
study, Campbell et al [17] demonstrated an increase in AHR
to methacholine following immunoneutralization of IL-18.
Similarly, Kodama et al [18] demonstrated significantly
higher levels of lung eosinophilia in IL-18 deficient mice in
an ovalbumin model of allergic airway disease and demon-
strate that, in vivo, IL-18 inhibited antigen-specific Th2
development. In contrast, administration of recombinant
murine IL-18 has been shown to increase allergic sensitiza-
tion, Th2 cytokine production, and airway eosinophilia in a
ragweed model of murine allergic asthma [28]. This data sug-
gests that IL-18 may promote a Th2 phenotype in vivo and
potently induce allergic sensitization [28]. In the present
study, AHR was significantly elevated 3 days after the coni-
dia challenge in anti-IL-18-treated mice. Interestingly, AHR
remained elevated at 30 days after conidia challenge in these
mice. The increase in AHR in anti-IL-18-treated mice at day
30 after conidia challenge may have been a result of a persis-
tent fungal antigen challenge and increased eosinophil num-
bers. In addition, profound peribronchial and interstitial
remodeling were observed in the lungs of IL-18 depleted
mice – all pathological features that are likely to contribute to
elevated AHR responses observed at this time point [29, 30].
Thus, increased AHR was a persistent feature of chronic fun-
gal asthma following an acute, 3-day, immunoneutralization
of IL-18.
The regulation of fibrosis and collagen deposition is a
dynamic event, involving synthesis and deposition of colla-
gen as well as degradation of existing basement membrane
components. Collagen deposition, subepithelial fibrosis, and
granuloma formation were markedly increased in the lungs
of IL-18-depleted mice 30 days after conidia challenge com-
pared with their NRS controls; these alterations could have
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Fig. 7. Effects of anti-IL-18 treatment in non-sensitized mice (A), A.
fumigatus-sensitized mice treated with NRS between days 0–3 after
conidia (B), and A. fumigatus-sensitized mice treated with anti-IL-18
anti-serum between days 0–3 after conidia challenge (C). mRNA was
isolated prior to, and 3, 7, and 30 days after, conidia challenge. Changes
in the levels of b-actin and TLR2 mRNA expression in whole lung
homogenates were measured by semi-quantitative RT-PCR. Induction
was expressed as a ratio of TLR2/b-actin mRNA density. Data is
expressed as means ± SEM of TLR2/b-actin ratios for 3 individual
experiments. *P < 0.05, **P < 0.01 and ***P < 0.0001 denotes signifi-
cant increases in TLR2 expression compared to levels measured prior to
conidia challenge.
been the consequence of a number of concurrent events.
First, the elevated eosinophil numbers detected in the lungs
of anti-IL-18-treated mice may have, in part, been responsi-
ble for the chronic structural changes observed in the air-
ways. Support for a role for eosinophils in pulmonary fibro-
sis has been drawn from clinical data showing a correlation
between lung eosinophil count and pulmonary fibrosis [31].
Furthermore, eosinophils are a major source for several key
pro-fibrogenic cytokines such as TGF-b and TNF-a. In vitro
studies that have shown that eosinophils, via elaboration of
both cytokines, can stimulate fibroblast proliferation and
contribute to profibrotic events [31]. Second, the release of
matrix metalloproteinases (MMPs) may also play a key role
in this interaction. MMPs are generally accepted as impor-
tant mediators of proteolytic activity during many physiolog-
ical and pathological remodeling processes [32], and the reg-
ulation of MMP release and activity appears to be altered in
the lungs of asthmatics [33]. While there are no previous
studies showing that IL-18 directly influences collagen depo-
sition and subepithelial fibrosis, we investigated, in the pre-
sent study, the role of MMP-2. Preliminary results in vitro
suggest that IL-18 increases MMP-2 expression in alveolar
macrophages, leading to the speculation that the lack of IL-
18 may have suppressed MMP-2 expression thereby leading
to impaired degradation of collagen. However, we are cur-
rently investigating the modulation of MMP levels within the
whole lung in a follow up study, as epithelial cells in addition
to alveolar macrophages produce MMPs. Finally, increased
airway remodeling 30 days after conidia challenge may have
also been a consequence of delayed conidia clearance. Inter-
estingly, the immunoneutralization of IL-18 in conidia-chal-
lenged mice provoked major interstitial remodeling as evi-
denced by granuloma formation. Sugawara et al [25]
observed that larger granulomatous regions formed in the
lungs of IL-18 deficient mice following Mycobacterium
tuberculosis infection compared to wild type controls. These
results reinforce those obtained in the present study, whereby
immunoneutralization of IL-18 led to the formation of
granulomas in the lungs of A. fumigatus-sensitized mice
30 days after conidia challenge, while no granulomas were
observed in mice that received NRS during the conidia chal-
lenge.
The present study also addressed the impact of IL-18 on
TLR2 expression during allergic airway disease. In addition
to clearance of conidia by neutrophils in IL-18-depleted
mice, fungal recognition via specific receptors on immune
cells may have been altered in allergic mice. Toll-like recep-
tors have been identified as key participants in the recogni-
tion of infectious agents and activation of the innate immune
response. Toll was initially identified as a key protein in the
development of the Drosophila body plan, however, later in
the fly’s life, this protein is involved in the defensive response
to fungal infection [19]. Consistent with previous studies
[34], constitutive TLR2 mRNA expression was observed in
whole lung homogenates from non-sensitized mice prior to
conidia challenge, while A. fumigatus-sensitization abrogat-
ed this constitutive TLR2 mRNA. Following conidia chal-
lenge, TLR2 mRNA expression is upregulated in both non-
sensitized and A. fumigatus-sensitized mice – with much
higher expression noted in non-sensitized mice. Delayed, or
suppressed, TLR2 mRNA expression following A. fumigatus
sensitization correlates with the delay in clearance of fungal
conidia in these mice compared to non-sensitized mice. Fur-
ther, TLR2 mRNA expression after conidia challenge in IL-
18-depleted mice is suppressed until day 30 after conidia,
which correlates with the increased retention of conidia in
the lungs of these mice. Decreased, or delayed, TLR2 expres-
sion appears to prevent efficient clearance of conidia from
the lungs, and persistence of conidia in the lungs may lead to
the onset of exacerbated allergic airway disease, fibrosis, and
remodeling. The avalability of suitable reagents limits the
study of TLR2’s role in this disease, however, we await the
accessibility of TLR2 knockout to fully investigate the role of
TLR2 in fungal clearance and pulmonary fibrosis. 
The results presented in this manuscript demonstrate the
important role of IL-18 in the innate response to a conidia
challenge in A. fumigatus-sensitized mice, possibly via the
recruitment of phagocytic leukocytes such as neutrophils
within the lung and regulation of recognition receptor
expression (i.e. TLR2). Delayed fungal clearance in the
absence of IL-18 impacted the development of allergic air-
way responses at later times points following conidia chal-
lenge, resulting in the exacerbation of AHR and dramatic air-
way and interstitial remodeling responses. 
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